Flies in the ointment: AAV vector preparations and tumor risk.
作者信息
Zhang Junping, Yu Xiangping, Herzog Roland W, Samulski R Jude, Xiao Weidong
机构信息
Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis, IN 46202, USA.
Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
出版信息
Mol Ther. 2021 Sep 1;29(9):2637-2639. doi: 10.1016/j.ymthe.2021.08.016. Epub 2021 Aug 26.
Abstract
摘要
相似文献
1
Flies in the ointment: AAV vector preparations and tumor risk.
Mol Ther. 2021 Sep 1;29(9):2637-2639. doi: 10.1016/j.ymthe.2021.08.016. Epub 2021 Aug 26.
2
Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors.
Cardiovasc Res. 2006 Apr 1;70(1):70-8. doi: 10.1016/j.cardiores.2005.12.017. Epub 2006 Jan 31.
3
The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
Mol Genet Metab. 2013 Nov;110(3):275-80. doi: 10.1016/j.ymgme.2013.06.014. Epub 2013 Jun 25.
4
Optimization of recombinant adeno-associated viral vectors for human beta-globin gene transfer and transgene expression.
Hum Gene Ther. 2008 Apr;19(4):365-75. doi: 10.1089/hum.2007.173.
5
CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice.
Hum Gene Ther. 2001 Mar 20;12(5):563-73. doi: 10.1089/104303401300042500.
6
7
JSRV Intragenic Enhancer Element Increases Expression from a Heterologous Promoter and Promotes High Level AAV-mediated Transgene Expression in the Lung and Liver of Mice.
Viruses. 2020 Nov 6;12(11):1266. doi: 10.3390/v12111266.
8
Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors.
Gene Ther. 2010 Jul;17(7):872-9. doi: 10.1038/gt.2010.27. Epub 2010 Mar 25.
9
Improved neuronal transgene expression from an AAV-2 vector with a hybrid CMV enhancer/PDGF-beta promoter.
J Gene Med. 2005 Jul;7(7):945-55. doi: 10.1002/jgm.742.
10
Targeting of breast metastases using a viral gene vector with tumour-selective transcription.
Anticancer Res. 2011 May;31(5):1627-35.
引用本文的文献
1
Strategies to improve safety profile of AAV vectors.
Front Mol Med. 2022 Nov 1;2:1054069. doi: 10.3389/fmmed.2022.1054069. eCollection 2022.
2
Thorough molecular configuration analysis of noncanonical AAV genomes in AAV vector preparations.
Mol Ther Methods Clin Dev. 2024 Feb 19;32(1):101215. doi: 10.1016/j.omtm.2024.101215. eCollection 2024 Mar 14.
3
Stowaways in the cargo: Contaminating nucleic acids in rAAV preparations for gene therapy.
Mol Ther. 2023 Oct 4;31(10):2826-2838. doi: 10.1016/j.ymthe.2023.07.025. Epub 2023 Aug 2.
4
Gene therapy for urea cycle defects: An update from historical perspectives to future prospects.
J Inherit Metab Dis. 2024 Jan;47(1):50-62. doi: 10.1002/jimd.12609. Epub 2023 Apr 18.
5
Genomic Designs of rAAVs Contribute to Pathological Changes in the Livers and Spleens of Mice.
Adv Cell Gene Ther. 2022;2022. doi: 10.1155/2022/6807904. Epub 2022 Mar 20.
6
Subgenomic particles in rAAV vectors result from DNA lesion/break and non-homologous end joining of vector genomes.
Mol Ther Nucleic Acids. 2022 Aug 24;29:852-861. doi: 10.1016/j.omtn.2022.08.027. eCollection 2022 Sep 13.
7
Evaluating the state of the science for adeno-associated virus integration: An integrated perspective.
Mol Ther. 2022 Aug 3;30(8):2646-2663. doi: 10.1016/j.ymthe.2022.06.004. Epub 2022 Jun 10.
本文引用的文献
1
A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells.
Nat Biotechnol. 2021 Jan;39(1):47-55. doi: 10.1038/s41587-020-0741-7. Epub 2020 Nov 16.
2
Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
Mol Ther. 2020 Sep 2;28(9):2073-2082. doi: 10.1016/j.ymthe.2020.06.001. Epub 2020 Jun 10.
3
VISDB: a manually curated database of viral integration sites in the human genome.
Nucleic Acids Res. 2020 Jan 8;48(D1):D633-D641. doi: 10.1093/nar/gkz867.
4
Adeno-associated virus in the liver: natural history and consequences in tumour development.
Gut. 2020 Apr;69(4):737-747. doi: 10.1136/gutjnl-2019-318281. Epub 2019 Aug 2.
5
Identification of liver-specific enhancer-promoter activity in the 3' untranslated region of the wild-type AAV2 genome.
Nat Genet. 2017 Aug;49(8):1267-1273. doi: 10.1038/ng.3893. Epub 2017 Jun 19.
6
Recombinant Adeno-Associated Viral Integration and Genotoxicity: Insights from Animal Models.
Hum Gene Ther. 2017 Apr;28(4):314-322. doi: 10.1089/hum.2017.009.
7
Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma?
Hum Gene Ther. 2015 Dec;26(12):779-81. doi: 10.1089/hum.2015.29014.kib.
8
Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas.
Nat Genet. 2015 Oct;47(10):1187-93. doi: 10.1038/ng.3389. Epub 2015 Aug 24.
9
Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy.
J Clin Invest. 2015 Feb;125(2):870-80. doi: 10.1172/JCI79213. Epub 2015 Jan 20.
10
Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction.
Hum Gene Ther. 2013 May;24(5):520-5. doi: 10.1089/hum.2012.112.
Zotero 插件